NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $3.11 +0.03 (+0.97%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.18 +0.07 (+2.35%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZNTL alerts:Sign Up Key Stats Today's Range$2.99▼$3.1850-Day Range$3.08▼$5.1152-Week Range$1.21▼$6.95Volume1.26 million shsAverage Volume812,555 shsMarket Capitalization$222.89 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingHold Company Overview Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers. WEE1 inhibition is intended to interfere with cancer cells’ ability to repair DNA damage and progress through the cell cycle. The company was founded in 2014 and is headquartered in San Diego, California. Zentalis became a publicly traded company in 2020. Its operations are primarily focused on the research and clinical development of oncology therapies, with clinical activities conducted through research institutions and trial sites in the United States and other regions. Kimberly J. Blackwell, M.D., is the company’s founder and chief executive officer.AI Generated. May Contain Errors. Read More Zentalis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreZNTL MarketRank™: Zentalis Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 194th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialZentalis Pharmaceuticals has a consensus price target of $6.75, representing about 117.0% upside from its current price of $3.11.Amount of Analyst CoverageZentalis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.11) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zentalis Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.24% of the float of Zentalis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 5.13.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently decreased by 16.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.17 News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for ZNTL on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $15,172,500.00 in company stock, which represents 6.8071% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,172,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.80% of the stock of Zentalis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsZentalis Pharmaceuticals has minimal institutional ownership at this time.Read more about Zentalis Pharmaceuticals' insider trading history. Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZNTL Stock News HeadlinesComparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Sol-Gel Technologies (NASDAQ:SLGL)September 16 at 4:29 AM | americanbankingnews.comZentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by BrokeragesSeptember 10, 2026 | americanbankingnews.comZentalis to present at Wells Fargo, Morgan Stanley eventsSeptember 2, 2026 | msn.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 SharesAugust 20, 2026 | insidertrades.comSee More Headlines ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $1.35 at the start of the year. Since then, ZNTL stock has increased by 130.4% and is now trading at $3.11. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.10. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $156 million in an initial public offering on Friday, April 3rd 2020. The company issued 9,180,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Top institutional shareholders of Zentalis Pharmaceuticals include 5AM Venture Management LLC (5.51%), BlackRock Inc. (5.27%), Bank of America Corp DE (1.56%) and Primecap Management Co. CA (1.34%). Insiders that own company stock include Group Walters, Matrix Capital Management Comp, Cam Gallagher, Melissa B Epperly, Scott Dunseth Myers, Kimberly Blackwell, Mark Lackner, Jan Skvarka, Vincent Vultaggio, David Michael Johnson, Carrie Brownstein and Ingmar Bruns. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Home Depot (HD), Chevron (CVX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/06/2026Today9/19/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, ZNTL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZNTL CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees106Year Founded2014Price Target and Rating Average Price Target for Zentalis Pharmaceuticals$6.75 High Price Target$11.00 Low Price Target$2.00 Potential Upside/Downside+117.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$137.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.18% Return on Assets-51.46% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$67.43 million Price / Sales3.31 Cash FlowN/A Price / Cash FlowN/A Book Value$2.99 per share Price / Book1.04Miscellaneous Outstanding Shares71,670,000Free Float68,948,000Market Cap$222.89 million OptionableOptionable Beta1.85 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ZNTL) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts